Granulocyte Colony-Stimulating Factor Increases CD4+ T Cell Counts of Human Immunodeficiency Virus-Infected Patients Receiving Stable, Highly Active Antiretroviral Therapy: Results from a Randomized, Placebo-Controlled Trial

• Published in: The Journal of infectious diseases Vol. 181; no. 3; pp. 1148 - 1152
• Main Authors: Aladdin, Hassan, Ullum, Henrik, Nielsen, Susanne Dam, Espersen, Christina, Mathiesen, Lars, Katzenstein, Terese L., Gerstoft, Jan, Skinhoj, Peter, Pedersen, Bente Klarlund
• Format: Journal Article
• Language: English
• Published: United States University Chicago Press 01.03.2000; University of Chicago Press
• Subjects: Adult; Aged; Blood; CD4 Lymphocyte Count - drug effects; Concise Communications; Female; Granulocyte Colony-Stimulating Factor - pharmacology; Granulocytes; Highly active antiretroviral therapy; HIV; HIV Infections - drug therapy; HIV Infections - immunology; Humans; Interleukin-2 - biosynthesis; Killer Cells, Natural - drug effects; Killer Cells, Natural - immunology; Lymphocyte Activation - drug effects; Lymphocytes; Male; Middle Aged; Natural killer cells; Neutrophils; Placebos; T lymphocytes; Viruses

Thirty human immunodeficiency virus (HIV)-infected patients with CD4+ T cell counts <350 cells/mm3 who had received stable, highly active antiretroviral therapy (HAART) for at least 24 weeks were randomized to receive either placebo or granulocyte colony-stimulating factor (G-CSF; 0.3 mg/mL 3 tim...